Applying proteomics to the diagnosis and treatment of ALS and related diseases

Muscle and Nerve

Volumn 40, Issue 5, 2009, Pages 753-762

  Bowser, Robert ^a   Lacomis, David ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; Motor neuron disease; Proteomics

Indexed keywords

AMYOTROPHIC LATERAL SCLEROSIS; CEREBROSPINAL FLUID; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG LABELING; ENZYME LINKED IMMUNOSORBENT ASSAY; FOOD AND DRUG ADMINISTRATION; GENETIC ANALYSIS; HUMAN; KENNEDY DISEASE; MOTOR UNIT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PLASMA; PRIMARY LATERAL SCLEROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SERUM; SPINAL MUSCULAR ATROPHY; TRANSCRANIAL MAGNETIC STIMULATION; URINE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; BIOLOGICAL MARKERS; HUMANS; NERVOUS SYSTEM DISEASES; PROTEOMICS;

EID: 71549118827     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21488     Document Type: Review

References (58)

1. Wang CH, Finkel RS, Bertini ES, Schroth M, Simonds A, Wong B, et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol 2007;22:1027-1049. (Pubitemid 47308318)
2. Singer MA, Statland JM, Wolfe GI, Barohn RJ. Primary lateral sclerosis. Muscle Nerve 2007;35:291-302.
3. Salinas S, Proukakis C, Crosby A, Warner TT. Hereditary spastic paraplegia: clinical features and pathogenetic mechanisms. Lancet Neurol 2008;7:1127-1138.
4. Group BDW. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
5. Wagner JA, Williams SA, Webster CJ. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther 2007;81: 104-107.
6. Iwata NK, Aoki S, Okabe S, Arai N, Terao Y, Kwak S, et al. Evaluation of corticospinal tracts in ALS with diffusion tensor MRI and brainstem stimulation. Neurology 2008;70: 528-532. (Pubitemid 351653377)
7. Mitsumoto H, Ulug AM, Pullman SL, Gooch CL, Chan S, Tang M-X, et al. Quantitative objective markers for upper and lower motor neuron dysfunction in ALS. Neurology 2007;68:1402-1410. (Pubitemid 46659092)
8. Kaufmann P, Pullman SL, Shungu DC, Chan S, Hays AP, Del Bene ML, et al. Objective tests for upper motor neuron involvement in amyotrophic lateral sclerosis (ALS). Neurology 2004;62:1753-1757. (Pubitemid 38661730)
9. Butman JA, Floeter MK. Decreased thickness of primary motor cortex in primary lateral sclerosis. Am J Neuroradiol 2007;28:87-91.
10. Kolarcik C, Bowser R. Plasma and cerebrospinal fluid-based protein biomarkers for motor neuron disease. Mol Diagn Ther 2006;10:281-292. (Pubitemid 44564828)
11. Ryberg H, Bowser R. Protein biomarkers for amyotrophic lateral sclerosis. Expert Rev Proteomics 2008;5:249-262.
12. Sussmuth SD, Brettschneider J, Ludolph AC, Tumani H. Biochemical markers in CSF of ALS patients. Curr Med Chem 2008;15:1788-1801.
13. Turner MR, Kiernan MC, Leigh NP, Talbot K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol 2009;8: 94-109.
14. Marouga R, David S, Hawkins E. The development of the DIGE system: 2D fluorescence difference gel analysis technology. Anal Chim Acta 2005;382:669-678. (Pubitemid 40890994)
15. Brettschneider J, Mogel H, Lehmensiek V, Ahlert T, Sussmuth S, Ludolph AC, et al. Proteome analysis of cerebrospinal fluid in amyotrophic lateral sclerosis (ALS). Neurochem Res 2008;33:2358-2363.
16. Anderson K, Potter A, Baban D, Davies KE. Protein expression changes in spinal muscular atrophy revealed with a novel antibody array technology. Brain 2003;126: 2052-2064. (Pubitemid 37059445)
17. Mitchell RM, Freeman WM, Randazzo WT, Stephens HE, Beard JL, Simmons Z, et al. A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis. Neurology 2009;72:14-19.
18. Anderson NL, Anderson NG. The human plasma proteome. Mol Cell Proteomics 2002;1:845-867.
19. Ramstrom M, Ivonin I, Johansson A, Askmark H, Markides KE, Zubarev R, et al. Cerebrospinal fluid protein patterns in neurodegenerative disease revealed by liquid chromatography- Fourier transform ion cyclotron resonance mass spectrometry. Proteomics 2004;4:4010-4018. (Pubitemid 39662757)
20. Ranganathan S, Williams E, Ganchev P, Gopalakrishnan V, Lacomis D, Urbinelli L, et al. Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J Neurochem 2005;95:1461-1471. (Pubitemid 41779269)
21. Pasinetti GM, Ungar LH, Lange DJ, Yemul S, Deng H, Yuan X, et al. Identification of potential CSF biomarkers in ALS. Neurology 2006;66:1218-1222. (Pubitemid 43739707)
22. Ranganathan S, Nicholl GCB, Henry S, Lutka F, Sathanoori R, Lacomis D, et al. Comparative proteomic profiling of cerebrospinal fluid between living and post mortem ALS and control subjects. Amyotroph Lat Scler 2007;8:373-379.
23. Wolf-Yadlin A, Hautaniemi S, Lauffenburger DA, White FM. Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks. Proc Natl Acad Sci U S A 2007;104:5860-5865. (Pubitemid 47175624)
24. Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lat Scler 2000;1:293-299.
25. Mitsumoto H, Santella RM, Liu X, Bogdanov M, Zipprich J, Wu HC, et al. Oxidative stress biomarkers in sporadic ALS. Amyotroph Lat Scler 2008;9:177-183. (Pubitemid 351983180)
26. Baloh RH, Rakowicz W, Gardner R, Pestronk A. Frequent atrophic groups with mixed-type myofibers is distinctive to motor neuron syndromes. Muscle Nerve 2007;36:107-110. (Pubitemid 47016169)
27. Pradat PF, Bruneteau G, Gonzalez de Aguilar JL, Dupuis L, Jokic N, Salachas F, et al. Muscle Nogo-A expression is a prognostic marker in lower motor neuron syndromes. Ann Neurol 2007;62:15-20. (Pubitemid 47235276)
28. Magnusson C, Libelius R, Tagerud S. Nogo (Reticulon 4) expression in innervated and denervated mouse skeletal muscle. Mol Cell Neurosci 2003;22:298-307. (Pubitemid 36407593)
29. Askanas V, Woicik S, Engel WK. Expression of Nogo-A in human muscle fibers is not specific for amyotrophic lateral sclerosis. Ann Neurol 2007;62:676.
30. Lacomis D. The use of percutaneous needle muscle biopsy in the diagnosis of myopathy. Curr Rheum Rep 2000;2: 225-229.
31. Jurisicova A, Jurisica I, Kislinger T. Advances in ovarian cancer proteomics: the quest for biomarkers and improved therapeutic interventions. Expert Rev Proteomics 2008;5: 551-560.
32. Gramolini AO, Kislinger T, Alikhani-Koopaei R, Fong V, Thompson NJ, Fagan A, et al. Comparative proteomics profiling of a phospholamban mutant mouse model of dilated cardiomyopathy reveals progressive intracellular stress responses. Mol Cell Proteomics 2008;7:519-533.
33. Poon HF, Hensley K, Thongboonkerd V, Merchant ML, Lynn BC, Pierce WM, et al. Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice-a model of familial amyotrophic lateral sclerosis. Free Radic Biol Med 2005;39:453-462. (Pubitemid 41021644)
34. Lukas TJ, Luo WW, Mao H, Cole N, Siddique T. Informatics- assisted protein profiling in a transgenic mouse model of amyotrophic lateral sclerosis. Mol Cell Proteomics 2006;5:1233-1244.
35. Schrohl A-S, Wurtz S, Kohn E, Banks RE, Nielsen HJ, Sweep FCGJ, et al. Banking of biological fluids for studies of disease- associated protein biomarkers. Mol Cell Proteomics 2008;7:2061-2066.
36. Paulovich AG, Whiteaker JR, Hoofnagle AN, Wang P. The interface between biomarker discovery and clinical validation: the tar pit of the protein biomarker pipeline. Proteomics Clin Appl 2008;2:1386-1402.
37. Pasinelli P, Brown RH. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Neurosci 2006;7: 710-723. (Pubitemid 44267495)
38. Gros-Louis F, Gaspar C, Rouleau GA. Genetics of familial and sporadic amyotrophic lateral sclerosis. Biochem Biophys Acta 2006;1762:956-972. (Pubitemid 44781174)
39. Kwiatkowski TJJ, Bosco DA, LeClerc AL, Tamrazian E, Vanderburg CR, Russ C, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009;323:1205-1208.
40. Vance C, Rogeli B, Hortobagyi T, De Vos KJ, Nishimura AL, Sreedharan J, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009;323:1208-1211.
41. Valdmanis PN, Rouleau GA. Genetics of familial amyotrophic lateral sclerosis. Neurology 2008;70:144-152.
42. Lee JW, Hall M. Method validation of protein biomarkers in support of drug development or clinical diagnosis/prognosis. J Chromatogr B 2009;877:1259-1271.
43. Goodsaid FM, Frueh FW, Mattes W. Strategic paths for biomarker qualification. Toxicology 2008;245:219-233.
44. Sumner CJ, Kolb SJ, Harmison GG, Jeffries NO, Schadt K, Finkel RS, et al. SMN mRNA and protein levels in peripheral blood. Neurology 2006;66:1067-1073.
45. Monsinjon T, Andersen OK, Leboulenger F, Knigge T. Data processing and classification analysis of proteomic changes: a case study of oil pollution in the mussel, Mytilus edulis. Proteome Sci 2006;4:17.
46. Mischak H, Apweiler R, Banks RE, Conaway M, Coon J, Dominiczak A, et al. Clinical proteomics: a need to define the field and to begin to set adequate standards. Proteomics Clin Appl 2007;1:148-156.
47. Ranganathan S, Polshyna A, Nicholl G, Lyons-Weiler J, Bowser R. Assessment of protein stability in cerebrospinal fluid using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry protein profiling. Clin Proteomics 2006;2:91-102.
48. Taylor CF, Paton NW, Lilley KS, Binz PA, Julian RKJ, Jones AR, et al. The minimum information about a proteomics experiment (MIAPE). Nat Biotechnol 2007;25:887-893.
49. Waldman S, Terzic A. Targeted diagnostics and therapeutics for individualized patient management. Biomarkers Med 2007;1:3-8.
50. Beuche W, Yushchenko M, Mader M, Maliszewska M, Felgenhauer K, Weber F. Matrix metalloproteinase-9 is elevated in serum of patients with amyotrophic lateral sclerosis. Neuroreport 2000;11:3419-3422.
51. Cronin S, Greenway MJ, Ennis S, Kieran D, Green A, Prehn JHM, et al. Elevated serum angiogenin levels in ALS. Neurology 2006;67:1833-1836. (Pubitemid 44900762)
52. Sussmuth SD, Tumani H, Ecker D, Ludolph AC. Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum. Neurosci Lett 2003;353:57-60. (Pubitemid 37464619)
53. Lacomblez L, Doppler V, Beucler I, Costes G, Salachas F, Raisonnier A, et al. APOE: a potential marker of disease progression in ALS. Neurology 2002;58:1112-1114. (Pubitemid 34298558)
54. Keizman D, Rogowski O, Berliner S, Ish-Shalom M, Maimon N, Nefussy B, et al. Low-grade systemic inflammation in patients with amyotrophic lateral sclerosis. Acta Neurol Scand 2009;119:383-389.
55. Zhao Z, Lange DJ, Ho L, Bonini S, Shao B, Salton SR, et al. Vgf is a novel biomarker associated with muscle weakness in amyotrophic lateral sclerosis (ALS), with a potential role in disease pathogenesis. Int J Med Sci 2008;5:92-99. (Pubitemid 351880757)
56. Bilic E, Bilic E, Rudan I, Kusec V, Zurak N, Delimar D, et al. Comparison of the growth hormone, IGF-1 and insulin in cerebrospinal fluid and serum between patients with motor neuron disease and healthy controls. Eur J Neurol 2006;13:1340-1345. (Pubitemid 44736644)
57. Zetterberg H, Jacobsson J, Rosengren L, Blennow K, Andersen PM. Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype. Eur J Neurol 2007;14:1329-1333. (Pubitemid 350135296)
58. Brettschneider J, Petzold A, Submuth SD, Ludolph AC, Tumani H. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology 2006;66:852-856. (Pubitemid 43739759)